Lupus Foundation of America3d
Deucravacitinib Outperforms Other Biologic Therapies for Treatment of Cutaneous Lupus Erythematosus
In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus ...
Lupus Foundation of America7d
New Study Examines Progress and Challenges in Biologic Treatments for Pediatric Rheumatic Diseases Over 25 Years
In a new study, researchers reviewed the advancements and ongoing challenges in the development of biologic therapies and ...
Lupus Foundation of America9d
Becoming a Support System: How the LFA Helped Kim in Her Daughter’s Lupus Diagnosis
When her daughter Jessica was diagnosed with lupus, Kim didn’t know where to turn. Read our latest blog post to learn how the ...
Lupus Foundation of America13d
High-Dose BI655064 Shows Promising Results in Improving Renal Outcomes for People with Lupus Nephritis
In a new study, researchers evaluated the treatment effects of BI655064, an anti-CD40 monoclonal antibody, as an add-on ...
Lupus Foundation of America14d
Fate Therapeutics Announces Promising Initial Data from FT819 Phase 1 Study for Moderate to Severe Systemic Lupus Erythematosus
Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with moderate-to-severe systemic lupus erythematosus (SLE). The ongoing trial is ...
Lupus Foundation of America14d
Heart Disease in People With Lupus
Heart disease includes different conditions that affect the heart, but usually, when people talk about heart disease, they are referring to coronary artery disease (CAD). CAD is the most common type ...
Lupus Foundation of America8d
Patient-Physician Dialogue Tool
The Patient-Physician Dialogue Tool (PDF) is a guide to support people going through the process of diagnosis. It includes a checklist and some pointers on questions to ask to make the most of your ...